Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110580 | 0.84 | GCGR (0.33) | GCGR | |
| SCHEMBL2894657 | 0.78 | AOC1 (0.40) | — | |
| SCHEMBL13028956 | 0.76 | — | — | |
| SCHEMBL28944228 | 0.75 | CYP2E1 (0.35) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL23641297 | 0.74 | GRM5 (0.44) | GCGRADRA2AADRA2BADRA2CHTR1A | |
| Ammonia Solution, Strong SCHEMBL28821972 | 0.74 | CYP2E1 (0.34) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL7074479 | 0.74 | CYP2E1 (0.34) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL21358990 | 0.72 | NOS2 (0.40) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL19703040 | 0.72 | CYP2E1 (0.33) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL27522603 | 0.72 | CYP2E1 (0.33) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246963-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | GCGR 748/4885CYP2E1 863/4885CYP2C8 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.